Title
A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus
A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of GRC 8200, a New Oral DPP -IV Inhibitor, in Patients With Type 2 Diabetes Mellitus.
Phase
Phase 2Lead Sponsor
Glenmark PharmaceuticalsStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Type 2 Diabetes MellitusIntervention/Treatment
grc 8200 ...Study Participants
480The study is aimed at evaluating efficacy and safety of GRC 8200 in type 2 diabetes mellitus patients.
The study involves six weeks of wash out period and two weeks run in period for patients currently on mono-therapy and a two week run in period only for drug naïve patients.
This is a placebo controlled study. One of the five treatment arms is placebo. The duration of treatment is 12 weeks.
Inclusion Criteria: Male or female patients ≥30 years of age At screening, females of non-childbearing potential or females of childbearing potential with adequate contraception Has an established clinical diagnosis of type 2 diabetes mellitus for at least 3 months prior to the screening period Is being treated for diabetes either with diet and exercise alone, or on monotherapy with any of the antidiabetic drugs Has an HbA1c value at screening between 6.5% and 10% Exclusion Criteria: Has type 1 diabetes Is a female who is lactating or is pregnant Has a history of acute metabolic diabetic complications Has clinically significant disease other than type 2 diabetes mellitus